Drug Master file Service by CPPL

A Drug Master File, also known as DMF, is a document that is voluntarily submitted by a pharmaceutical manufacturer to the appropriate regulatory authority in the intended drug market. It is important to note that there is no mandatory requirement to file a DMF. This document serves to provide the regulatory authority with confidential and detailed information about the manufacturing, processing, packaging, and storing of one or more human drugs. Typically, a drug master file is filed when multiple firms collaborate in the development or production of a drug product. The purpose of filing a DMF is to allow a firm to safeguard its intellectual property from its partner, while still adhering to regulatory requirements regarding the disclosure of processing details.

A Drug Master File (DMF) is a submission that is voluntarily provided to the Food and Drug Administration (FDA) by a pharmaceutical manufacturer. It contains confidential and detailed information about the facilities, processes, and articles used in the production of human drugs. Submitting a DMF is not mandatory according to regulatory requirements, but it allows the regulatory authority to have access to important information while protecting the intellectual property of the manufacturer. The information in a DMF can be used in various applications, such as an Investigation New Drug Application (IND) or a New Drug Application (NDA). It is important to note that a DMF is not a substitute for an IND, NDA, or any other application, and its technical contents are only reviewed in connection with these applications. The guidelines provided do not impose mandatory requirements, but rather offer guidance on meeting regulatory expectations. It is advisable for the applicant to discuss variations in advance with FDA reviewers to ensure the submission's acceptability. The procedures outlined in this guideline are intended to assist DMF holders in the preparation and submission of their files, and cover various aspects such as types of DMFs, required information, submission formats, review procedures, and the responsibilities of the DMF holder.

Various strategies may be used, but in order to avoid wasting time and resources on preparing a submission that the FDA may ultimately find to be undesirable, the applicant is recommended to address any significant alterations in advance with FDA reviewers. 21 CFR 314.420 provides for drug master files. The purpose of this guideline is to give DMF holders the methods that the agency will accept for creating and submitting a DMF. The guidelines include the many kinds of DMFs, the data required for each kind, the format for submissions to a DMF, the administrative processes controlling DMF reviews, and the responsibilities of the DMF holder. DMFs are often made to let material to be cited by parties other than the DMF holder without revealing the file's contents to that party. Rather than creating a new DMF, an applicant referencing its own material should directly refer to the information found in its own IND, NDA, or ANDA.

CPPL is an authorised agent for US DMF submissions and has extensive expertise writing DMFs. To date, we have filed over 400 DMFs to various international authorities. Many small-scale manufacturers are confused about the differences between writing and compiling dossiers. Writing a dossier requires technical skills, such as studying and reviewing the client's technical documentation, whereas compiling a dossier is simply document formatting, which can be done by anyone without technical experience. With the help of its knowledgeable industrial workforce and competent technical staff, CPPL guarantees total compliance with regulatory standards.